×
About 10,165 results

ALLMedicine™ Alopecia Center

Research & Reviews  3,080 results

Assessment of Changes in Diversity in Dermatology Clinical Trials Between 2010-2015 and...
https://doi.org/10.1001/jamadermatol.2021.5596
JAMA Dermatology; Chen V, Akhtar S et. al.

Jan 27th, 2022 - Although there have been increased efforts in dermatologic research to improve representation of patient sex, race, and ethnicity, there are limited data evaluating resulting changes. To characterize the diversity of participants in dermatologic c...

Advances in dermatology in sub-Saharan Africa in the past 20 years from workshops to th...
https://doi.org/10.1111/ijd.16073
International Journal of Dermatology; Verschoore M, Dlova N

Jan 27th, 2022 - Highly pigmented African skin and hair have distinct characteristics because of their unique physiology and structure. Twenty years ago, despite an increasing number of dermatology specialists in some African countries, there remained a paucity of...

The Association between Frontal Fibrosing Alopecia, Sunscreen, and Moisturizers: A Syst...
https://doi.org/10.1016/j.jaad.2021.12.058
Journal of the American Academy of Dermatology; Maghfour J, Ceresnie M et. al.

Jan 26th, 2022 - The Association between Frontal Fibrosing Alopecia, Sunscreen, and Moisturizers: A Systematic Review with a Meta-Analysis.|2022|Maghfour J,Ceresnie M,Olson J,Lim HW,|

Plasma Cell-Predominant Lichen Planopilaris.
https://doi.org/10.1097/DAD.0000000000002059
The American Journal of Dermatopathology; Frew D, Oaxaca G et. al.

Jan 26th, 2022 - Lichen planopilaris (LPP) is a scarring alopecia that is characterized by a lichenoid interface infiltrate with follicular extension. We present a case of LPP composed predominantly of plasma cells in a 52-year-old man. The patient was originally ...

KLHL24-mediated hair follicle stem cells structural disruption causes alopecia.
https://doi.org/10.1016/j.jid.2022.01.007
The Journal of Investigative Dermatology; Cui J, Zhao Q et. al.

Jan 24th, 2022 - Kelch-like protein 24 (KLHL24) is an E3 ubiquitin ligase. Mutations in the start codon of KLHL24 result in truncated KLHL24 protein lacking the initial 28 amino acids (KLHL24-ΔN28). KLHL24-ΔN28 is more stable than wide-type KLHL24 and causes exces...

see more →

Guidelines  3 results

Guidelines for the diagnosis and treatment of male-pattern and female-pattern hair loss...
https://doi.org/10.1111/1346-8138.14470
The Journal of Dermatology; Manabe M, Tsuboi R et. al.

Jun 5th, 2018 - Male-pattern hair loss (MPHL, androgenetic alopecia) is a slowly progressive form of alopecia which begins after puberty. In 2010, we published the first Japanese edition of guidelines for the diagnosis and treatment of MPHL. It achieved the origi...

Guidelines for management of androgenetic alopecia based on BASP classification--the As...
https://doi.org/10.1111/jdv.12034
Journal of the European Academy of Dermatology and Venere... Lee WS, Lee HJ et. al.

Nov 28th, 2012 - Androgenetic alopecia (AGA), or pattern hair loss, is a common disorder in both Asian men and women. There are several guidelines for the treatment of AGA which are suitable for Caucasian patients; however, each of these has some limitations. Furt...

British Association of Dermatologists' guidelines for the management of alopecia areata...
https://doi.org/10.1111/j.1365-2133.2012.10955.x
The British Journal of Dermatology; Messenger AG, McKillop J et. al.

Apr 25th, 2012 - British Association of Dermatologists' guidelines for the management of alopecia areata 2012.|2012|Messenger AG,McKillop J,Farrant P,McDonagh AJ,Sladden M,|diagnosis,etiology,therapy,methods,therapeutic use,methods,methods,methods,

see more →

Drugs  270 results see all →

Clinicaltrials.gov  139 results

Extension Study to Evaluate Safety and Efficacy of CTP-543 in Adults With Alopecia Areata
https://clinicaltrials.gov/ct2/show/NCT03898479

Jan 21st, 2022 - The overall objectives of the study are to evaluate long-term safety of CTP-543 and to assess long-term effects of CTP-543 on treating hair loss in adult patients with chronic, moderate to severe alopecia areata.

Topical Crisaborole in Patients With Alopecia Areata
https://clinicaltrials.gov/ct2/show/NCT04299503

Jan 21st, 2022 - Each individual will be enrolled in the study for 24 weeks. Following a 28 days screening period, eligible subjects will be randomized in a 1:1 ratio to receive either crisaborole 2% ointment or matching placebo for 12 weeks. The primary endpoint ...

European Extension Study to Evaluate Safety and Efficacy of CTP-543 in Adults With Alopecia Areata
https://clinicaltrials.gov/ct2/show/NCT05041803

Jan 21st, 2022 - The overall objectives of the study are to evaluate long-term safety of CTP-543 and to assess long-term effects of CTP-543 on treating hair loss in adult patients with chronic, moderate to severe alopecia areata. Patients from European sites who p...

Hair-Safe Study: Scalp Cooling for Hair Saving in Women Undergoing Chemotherapy
https://clinicaltrials.gov/ct2/show/NCT04117815

Jan 20th, 2022 - Scalp cooling using cooling caps has been identified as an effective treatment option against CT-induced alopecia in numerous European countries. Originally, crashed ice was used to cause vasoconstriction and consequently diminish CT uptake to hai...

Observation or Radiation Therapy in Treating Patients With Newly Diagnosed Grade II Meningioma That Has Been Completely Removed by Surgery
https://clinicaltrials.gov/ct2/show/NCT03180268

Jan 18th, 2022 - PRIMARY OBJECTIVES: I. To determine, in terms of progression-free survival (PFS), the extent of clinical benefit of the addition of adjuvant radiotherapy (RT) to gross total resection (GTR) for patients with newly diagnosed World Health Organizati...

see more →

News  565 results

T-DXd for HER2+ Metastatic Breast Cancer
https://www.onclive.com/view/t-dxd-for-her2-metastatic-breast-cancer

Jan 20th, 2022 - Kevin Kalinsky, MD, MS: Let’s move along with this case. Her treatment course was complicated when she started to experience peripheral neuropathy, and she completed 9 of 14 cycles. Komal, how often do you feel like you see this in practice? Ko...

EMA Validates Type II Variation Application for Trastuzumab Deruxtecan in HER2+ Metastatic Breast Cancer
https://www.onclive.com/view/ema-validates-type-ii-variation-application-for-trastuzumab-deruxtecan-in-her2-metastatic-breast-cancer

Jan 3rd, 2022 - The European Medicines Agency (EMA) has validated the Type II Variation application for fam-trastuzumab deruxtecan-nxki (Enhertu) as a treatment for adult patients with unresectable or metastatic HER2-positive breast cancer who have previously rec...

Oral JAK Inhibitor Continues to Show Promise for Alopecia Areata
https://www.medscape.com/viewarticle/965750

Dec 30th, 2021 - NEW YORK (Reuters Health) - Treatment with the investigational oral Janus kinase (JAK) inhibitors ritlecitinib or brepocitinib led to molecular and clinical improvement in scalp lesions in patients with alopecia areata enrolled in a biopsy sub-stu...

Japanese Approval Sought for Trastuzumab Deruxtecan in HER2+ Metastatic Breast Cancer
https://www.onclive.com/view/japanese-approval-sought-for-trastuzumab-deruxtecan-in-her2-metastatic-breast-cancer

Dec 21st, 2021 - A supplemental new drug application (sNDA) has been submitted to Japan’s Ministry of Health, Labour, and Welfare (MHLW) for the use of fam-trastuzumab deruxtecan-nxki (Enhertu) as a treatment in patients with HER2-positive unresectable or recurren...

Vegetative Plaques on the Face
https://www.mdedge.com/dermatology/article/249888/dermatopathology/vegetative-plaques-face
Jack Lee, MD, Richard H. Flowers, MD

Dec 14th, 2021 - THE DIAGNOSIS: Vegetative Majocchi Granuloma A biopsy and tissue culture showed acute dermal inflammation with granulomatous features and numerous fungal hyphae within the stratum corneum (Figure 1A), which were confirmed on GrocottGomori methenam.

see more →

Patient Education  9 results see all →